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Abstract 
The maternal adaptation to pregnancy includes hyperlipidaemia, oxidative stress and chronic 
inflammation. In non-pregnant individuals these processes are usually associated with poor vascular 
function. However maternal vascular function is enhanced in pregnancy. It is not understood how 
this is achieved in the face of the adverse metabolic and inflammatory environment. Research into 
cardiovascular disease demonstrates that plasma high density lipoprotein (HDL), by merit of its 
functionality rather than its plasma concentration, exerts protective effects on the vascular 
endothelium. HDL has vaso-dilatory, anti-oxidant, anti-thrombotic and anti-inflammatory effects and 
can protect against endothelial cell damage. In pregnancy, plasma HDL concentration starts to rise at 
10 weeks’ gestation, peaking at 20 weeks. The initial rise in plasma HDL occurs around the time of 
the establishment of the feto-placental circulation, a time when the trophoblast plugs in the 
maternal spiral arteries are released generating oxidative stress. Thus there is the intriguing 
possibility that new HDL of improved function is synthesised around the time of the establishment of 
the feto-placental circulation. In obese pregnancy and to a greater extent in preeclampsia, plasma 
HDL levels are significantly decreased and maternal vascular function is reduced. Wire myography 
studies have shown an association between the plasma content of apolipoprotein AI, the major 
protein constituent of HDL, and blood vessel relaxation. These observations lead us to hypothesise 
that HDL concentration, and function, increases in pregnancy in order to protect the maternal 
vascular endothelium and that in preeclampsia this fails to occur. 
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Introduction 
There is a large body of research concerning the role of plasma HDL as a protective agent against 
cardiovascular disease. This has come from a wide variety of epidemiological studies, human clinical 
studies and, particularly with respect to the molecular function of HDL, from rodent animal models. 
However there is surprisingly little known about HDL in pregnancy. Research in humans remains 
limited to measurement of plasma concentration in healthy and complicated pregnancy whereas 
pregnant rodent models focus predominantly on metabolic programming of offspring rather than 
maternal adaptation to pregnancy. Here, the evidence for a role of HDL in maternal pregnancy in 
protecting vascular endothelium will be discussed incorporating the small amount of data available 
from human pregnancy and drawing parallels from the larger body of evidence, from humans and 
animals, in the wider cardiovascular field. 
Metabolic changes in healthy pregnancy 
The maternal adaptation to pregnancy involves significant metabolic change primarily to meet the 
demands of fetal growth and development (reviewed in1). In early pregnancy the mother becomes 
insulin sensitive in order to acquire adipose tissue required to supply fatty acids in later gestation. By 
the third trimester there is increased insulin resistance, hyperlipidaemia, increased inflammation 
and enhanced coagulation status. Oxidative stress increases with gestation as evidenced by an 
increase in markers of oxidative stress2.  Insulin resistance in healthy pregnant women preserves the 
supply of glucose to support the growing fetus and supports lipolysis from maternal adipose tissue 
providing fatty acids for placental transport1. In later gestation, high fatty acid supply to the liver 
results in hypertriglyceridaemia as a consequence of increased very low density lipoprotein (VLDL) 
secretion. Plasma total cholesterol and low density lipoprotein (LDL) concentrations also increase 
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but to a lesser extent1. Plasma high density lipoprotein (HDL) levels increase and reach their peak at 
mid gestation before declining in the last trimester3.  
 
Vascular function in pregnancy 
The metabolic and inflammatory changes described above would normally be associated with poor 
vascular function in non-pregnant individuals. High plasma lipid levels, in the presence of oxidative 
stress, leads to lipid peroxidation and production of reactive oxygen species (ROS) which are highly 
damaging to the vascular endothelium4. Gestational hypertriglyceridaemia also results in an increase 
in the production of highly atherogenic and easily oxidised small, dense LDL species1. However, 
pregnant women have enhanced vascular function. In healthy pregnancy, blood pressure 
progressively falls to reach a nadir at around 20 weeks mediated by a fall in maternal systemic 
vascular resistance due to vasodilation, followed by a gradual increase in blood pressure to reach 
pre-pregnancy levels. Studies looking at endothelium-dependent vascular function using flow-
mediated dilatation (FMD) of the brachial artery showed that pregnant women had a significantly 
higher increase in flow-mediated diameter than non-pregnant women, mediated at least in part by 
the endothelium-dependent vasodilator nitric oxide (NO)5. Flow-mediated dilatation progressively 
increased throughout gestation reaching a peak in the last trimester5. A positive correlation between 
percentage FMD and plasma triglyceride concentration confirms that pregnancy-related enhanced 
vascular function exists despite gestational hyperlipidaemia6. Microvascular function, both 
endothelium-dependent and endothelium-independent, determined using non-invasive laser 
Doppler imaging was also improved during gestation7.  Using wire myography, it has also been 
shown that small resistance arteries, isolated from healthy pregnant women, had better flow-
mediated relaxation than arteries from non-pregnant women8. It is not understood how improved 
vascular function is maintained in the face of a barrage of metabolic and inflammatory mediators 
normally associated with vascular damage. While the gestational period of nine months might 
appear to be a short time over which to influence vascular function by changes in the metabolite 
composition of plasma, there is an abundance of evidence showing that that the post-prandial 
increase in lipid concentration impairs vascular function in healthy individuals over a number of 
hours9.   
One study has looked at maternal HDL and endothelium-dependent brachial artery flow-mediated 
dilatation (FMD) in healthy pregnancy6. A multivariate analysis found a positive association between 
%FMD and plasma triglyceride, but no association with plasma HDL when both were entered into 
the model together. The authors interpreted this as the plasma triglyceride level reflecting the 
degree of maternal gestational adaptation driven by plasma estradiol levels and concluded that 
endothelial function improvement in pregnancy was likely due to the increased concentrations of 
HDL. It is difficult to interpret these data in light of the metabolic link between plasma triglyceride 
and HDL and the fact that plasma HDL concentration may not reflect HDL function (detailed later). 
Clearly more experimental data looking directly at the effects of HDL on vascular function are 
required. 
 
HDL has functions that protect the vascular endothelium 
HDL is a protein-rich and cholesteryl-ester rich lipoprotein complex and epidemiological studies 
show an inverse relationship between its plasma concentration and the risk of cardiovascular 
disease10. Its major protein constituent is apolipoprotein AI (Apo AI). HDL was initially thought to 
exert all its anti-atherogenic effects via its key role in reverse cholesterol transport, whereby HDL 
removes cholesterol from peripheral tissues and delivers it to the liver for excretion. HDL mediates 
cholesterol efflux from cells involving several cellular mechanisms such as protein kinase C 
activation, increasing cAMP concentration in macrophages and retroendocytosis11. However recent 
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clinical trials of inhibitors of an enzyme intrinsic to HDL metabolism, cholesteryl ester transfer 
protein (CETP), have demonstrated that despite effective increases in HDL plasma concentration, the 
risk of cardiovascular disease was unaffected or even increased12. Numerous studies support the 
notion that CETP mediates reverse cholesterol transport13. By inhibiting CETP, reverse cholesterol 
transport may also be blocked demonstrating that increased HDL concentration may not be 
beneficial in every instance, especially if it reflects decreased turnover14. Such clinical data 
emphasise the importance of differentiating plasma HDL steady state concentration from HDL 
function. Recent research focus has shifted away from the benefits of high plasma concentrations of 
HDL towards the study of specific HDL functions mediated by the proteins and lipids associated with 
the HDL particle (Figure 1). 
HDL enhances vasodilation of blood vessels at least in part by increasing the availability of NO. 
Endothelial NO is key for the regulation of vascular tone and structure. HDL regulates endothelial NO 
synthase (eNOS) expression15 and activity, stimulating NO production and inducing vasodilation16. An 
eNOS knockout mouse model confirmed the role of eNOS when the vasodilatory effect of HDL on 
aorta was lost in this animal17. Another study in scavenger receptor class B member 1 (SR-B1, a 
plasma membrane receptor for HDL) knockout mice using isolated HDL from pre- and post-
menopausal women demonstrated that HDL-associated estradiol stimulates eNOS activity via the 
SR-B1 receptor18. The sphingosine-1-phosphate (S1P) receptor also has a role in mediating eNOS 
activation by HDL17. These protective effects of HDL on endothelium dependent vasodilatation 
through NO production are lost in cardiovascular disease patients19.  
Other properties of HDL include antioxidant effects. HDL attenuates the oxidative stress produced by 
oxidised LDL and the smaller, denser subspecies of HDL have the most potent anti-oxidative 
effects20. HDL carries enzymes that act as antioxidants such as paraoxonase-1 (PON-1) and platelet 
activating factor acetyl hydrolase (PAF-AH)21.  In addition, integral HDL proteins such as apo AI can 
be sacrificed to oxidation to protect other molecules22. Reactive oxygen species (ROS) disrupt the 
active eNOS dimer and HDL can prevent oxidised LDL’s inhibitory effect on eNOS. HDL prevents LDL 
oxidation through inactivation of lipid hydroperoxides mediated by PON-123 and also via Apo AI 
which uses specific methionine residues to reduce peroxides into inactive lipid hydroxides24.  HDL 
PON-1 content determines the capacity of HDL to stimulate NO production and protect the 
endothelium25. Plasma HDL concentrations are associated with a reduced risk of venous 
thrombosis26. SR-B1 knock out mice, which have high plasma HDL concentrations, have low platelet 
levels possibly due to an alteration in platelet structure resulting in increased clearance27. HDL can 
increase the anticoagulant activities of protein S and activated protein C, an effect significantly 
reduced by anti-apo AI antibodies28. There is an inverse association between clot lysis time and 
plasma levels of HDL and apo AI which supports an anti-thrombotic role for HDL29. 
HDL inhibits TNFα-induced endothelial expression of adhesion molecules (ICAM-1 and VCAM-1) in 
human umbilical endothelial cells30. HDL exerts its anti-inflammatory action through the SR-B1 
receptor as siRNA against SR-B1 attenuated HDL’s inhibitory effect on adhesion molecule 
expression30. Lipopolysaccharide (LPS)-induced pro-inflammatory cytokines, such as TNF-α, ICAM-1 
and IL-6, were also reduced in THP-1 macrophages pre-treated with HDL31. Other anti-inflammatory 
effects of HDL and apo AI include inhibition of neutrophil activation, adhesion and infiltration32. HDL 
can protect against apoptosis of endothelial cells and damage the integrity of the endothelium 
monolayer33. HDL and apo AI can inhibit endothelial cell apoptosis mediated by oxidized LDL34. 
Isolated HDL from healthy subjects was able to inhibit the apoptosis of endothelial cells in vitro and 
in contrast, HDL isolated from coronary artery disease patients exerted a pro-apoptotic effect35. 
 
Sphingosine-1-phospate and HDL 
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Sphingosine-1-phosphate (S1P) is an HDL-associated lysophospholipid, anchored to the HDL particle 
via apolipoprotein M, whose levels correlate directly with HDL, apo AI and apo AII levels36. Smaller, 
denser HDL is found to carry approximately twice the amount of S1P than that carried by larger HDL 
species37. S1P is involved in many of HDL’s biological effects including vasodilation, anti-oxidative 
actions and anti-inflammatory functions38. S1P is the major contributor to HDL-related effects on 
blood vessel relaxation, Akt activation and eNOS phosphorylation as these effects are totally 
abolished in S1P3 receptor deficient mice17. S1P also plays an important part in the anti-oxidative 
properties of HDL by protecting against the cytotoxic effects of oxidised LDL39. S1P’s effects are 
complex and may act through different signaling pathways at different concentrations30.  
 
HDL and vascular function in pregnancy 
Plasma HDL concentrations increase throughout pregnancy3. Data from our laboratory, compiled 
using many samples collected at different gestations of pregnancy, shows a detailed profile of 
plasma HDL and triglyceride concentrations throughout pregnancy (Figure 2). Plasma triglyceride 
levels begin to increase substantially around 20 weeks’ gestation and continue to rise until delivery. 
After delivery there is a sharp fall to slightly below pre-pregnancy levels and a rebound to pre-
pregnancy levels by about 20 weeks post-partum. Plasma HDL concentration shows a different 
pattern. After an early slight decline in concentration, a rise in plasma HDL concentration is initiated 
at 10 weeks’ gestation, peaking at a maximum level of 42% increased concentration at 20 weeks’ 
gestation and declining to a plateau only 7% above early pregnancy levels by 30 weeks’ gestation. 
The post-partum decline in HDL concentration is delayed until about 10 weeks after delivery and 
eventually pre-pregnancy levels are reached by 20 weeks after delivery. 
The co-existence of high plasma HDL concentration, in the face of high plasma triglyceride 
concentration, is contrary to our metabolic understanding of the links between triglyceride and HDL 
metabolism in non-pregnant individuals. High plasma triglyceride in the non-pregnant population 
causes HDL and LDL to become enriched with triglyceride via the substrate-driven action of CETP. 
CETP facilitates the transfer of cholesteryl ester from HDL and LDL in exchange for triglyceride from 
VLDL. The resultant triglyceride rich-HDL is acted on by hepatic lipase leading to particle shrinkage 
and increased plasma HDL turnover thus linking high plasma triglyceride concentration with low 
plasma HDL40. Therefore in healthy pregnancy, high HDL concentration in the presence of high 
triglyceride concentration is unusual and this suggests that HDL metabolism becomes decoupled 
from triglyceride metabolism perhaps due to the estrogenic drive increasing HDL synthesis41. In 
addition, the timing of the increase in plasma HDL is interesting as concentrations begin to rise 
around the time of the establishment of the feto-placental circulation at 10-13 weeks’ gestation. At 
this time trophoblast plugs in the maternal spiral arteries which protect embryonic tissue from 
oxidative damage are released generating oxidative stress. Thus there is the intriguing possibility 
that new HDL of improved function is synthesised around the time of the establishment of the feto-
placental circulation and prior to the increase in plasma triglyceride.  
 
Maternal vascular function and plasma HDL in obese pregnancy and preeclampsia 
While both non-obese and obese pregnant women have improved endothelium-dependent vascular 
function compared to the non-pregnant state, non-obese mothers have better endothelium-
dependent microvascular function than obese mothers7. In addition, myometrial arteries isolated 
from pregnant women with high BMI (>36kg/m2) showed decreased relaxation to bradykinin 
compared to vessels obtained from pregnant women with non-obese BMI (<30kg/m2)42. Obese 
pregnancy is associated with metabolic syndrome in which plasma concentrations of triglyceride and 
VLDL are higher and concentrations of HDL lower than in non-obese pregnancy1, 7. It is possible that 
in obese pregnancy, HDL concentrations may be insufficient to fully protect the maternal vascular 
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endothelium and the obese pregnant woman is at higher risk of endothelial dysfunction increasing 
her risk for preeclampsia43.  
Preeclampsia, a multi-system disorder particular to pregnancy, is a leading cause of maternal and 
neonatal morbidity and mortality and is one of the most difficult challenges facing obstetric 
medicine. The disease is characterised by widespread endothelial dysfunction, resulting in 
hypertension due to vasoconstriction, proteinuria attributable to glomerular damage and oedema 
secondary to increased vascular permeability. It complicates 2-8% of pregnancies, eludes early 
detection and there is no effective intervention other than iatrogenic delivery. In preeclampsia the 
maternal metabolic adaptation to pregnancy is abnormal with development of metabolic syndrome 
features including hypertriglyceridaemia and reduced HDL1. Low pre-conception plasma HDL [odds 
ratio (OR) 1.61 (95%CI 1.29-2.01)] and high plasma triglycerides [OR 1.33 (95%CI 1.09-1.63)] were 
independently associated with preeclampsia and/or gestational diabetes mellitus after adjustment 
for maternal confounders44. Furthermore, there was a significant (P<0.001) interaction between low 
HDL and high triglycerides. A genetic predisposition to low plasma HDL is also associated with an 
increased risk of preeclampsia45.  In preeclampsia there is increased lipid peroxidation, antioxidant 
levels are reduced46 and plasma PON-1 levels are decreased 47. Maternal obesity, increased insulin 
resistance and aberrant fatty acid metabolism are involved in the pathogenesis of at least some 
phenotypes of preeclampsia48. Vascular dysfunction in preeclampsia has been observed both at the 
physiological level by a variety of techniques8, 49, 50 and in isolated blood vessels. In ex vivo wire 
myography studies, small resistance arteries derived from subcutaneous adipose tissue 
(representing systemic maternal vascular resistance) and myometrial biopsies (representing the 
vessels that supply the placenta) from preeclampsia pregnancy showed lower endothelium-
dependent relaxation than vessels from healthy pregnancy51, 52.  NO-, EDHF- and eicosanoid-
mediated pathways were implicated. Preincubation of myometrial vessels from healthy pregnancy 
with plasma from women with preeclampsia, even if plasma was sampled at a gestation prior to the 
clinical manifestation of preeclampsia, inhibited endothelium-dependent relaxation53. Interestingly, 
an association between the concentration of the major protein constituent of HDL, apo AI, in plasma 
and the vaso-relaxation was observed54. These effects are specific to gestational adaptive functions 
of the endothelium as no effects on vaso-relaxation were seen in non-pregnant vessels55.  
 
Hypothesis 
We hypothesise that establishment of the placental circulation triggers the formation of more 
and/or new, more effective, HDL as a pregnancy adaption that protects and enhances function of 
the vascular endothelium in the face of the oxidative, lipid and inflammatory stresses of healthy 
pregnancy. In healthy pregnancy, HDL is able to counter the oxidative and inflammatory stresses of 
the maternal adaptation to pregnancy. In preeclampsia, HDL fails to optimally adapt resulting in 
failure to protect the maternal endothelium resulting in vascular dysfunction. 
 
Future experimental work 
There are a number of questions regarding HDL in pregnancy that could be answered 
experimentally. Ex-vivo myography studies using vessels from pregnant animal models or in tissue 
from pregnant women can test whether HDL enhances vessel relaxation. Compositional studies 
including lipidomics and proteomics can test whether newly synthesised HDL in pregnancy differs 
from HDL in non-pregnant individuals. In vitro analysis of the vascular protective properties of HDL 
can demonstrate whether HDL from pregnant women has enhanced protective abilities as compared 
to HDL in the non-pregnant state.  Comparison of HDL from women with preeclampsia with HDL 
from healthy pregnancies can test whether HDL gestational adaptive changes fail to take place in 
preeclampsia.  
6 
 
 
Clinical implications of a vascular protective role for HDL in pregnancy 
An understanding of the role of HDL in preeclampsia could inform clinical understanding and shape 
future management of the disease. The well-recognised athero-protective effects of HDL have led to 
the development of therapeutic agents to raise HDL concentration or increase HDL function for the 
prevention of cardiovascular disease.  These agents include HDL infusing agents, recombinant LCAT, 
apo AI transcriptional upregulators and apo AI mimetic peptides56. Administration of synthetic HDL 
improves endothelial function in patients with hypercholesterolaemia57. Apo AI/phospholipid 
complexes and apo AI mimetics in CVD are in pre-clinical development58. Other studies showed HDL 
infusion was able to reduce atherogenic events including inflammation, thrombosis as well as 
apoptosis59.  If HDL in pregnancy exerts vascular protective effects, then trials of synthetic HDL and 
apo AI mimetics in preventing/managing preeclampsia could be indicated. In pregnancy it is difficult 
to recommend interventions other than diet or lifestyle, for safety reasons. The HDL mimetics have 
enormous potential utility in pregnancy as they would be safe to administer and would allow 
manipulation of HDL function as well as concentration. 
 
2,812 words 
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Figure 1. HDL protective actions at the endothelium. A number of the constituents of HDL may 
interact with the vascular endothelium. Production of nitric oxide (NO) induces blood vessel dilation. 
The main apolipoprotein on HDL, apoAI, may increase NO production via AMP-activated protein 
kinase (AMPK) signalling.  Sphingosine-1-phosphate (S1P) is a lipid anchored to the HDL particle via 
the apolipoprotein apoM, and it can interact with S1P1 and S1P3 receptors on the vascular 
endothelial cell leading to increased endothelial nitric oxide synthase (eNOS) activity, partly via 
AMPK pathways. HDL also carries the antioxidant enzyme paraoxonase-1 (PON-1). This enzyme, 
possibly in addition to other anti-oxidative effects of HDL, inhibits the oxidation of LDL to form 
oxidised LDL (OxLDL). PON-1 also can inhibit OxLDL receptor (LOX-1) activity thus reducing the 
production of reactive oxygen species (ROS) via NAHPH oxidase, and preventing the inhibitory 
effects of ROS on eNOS. 
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Figure 2  Maternal plasma HDL-cholesterol and plasma triglyceride concentrations during 
pregnancy and post partum. Unpublished data from a series of overlapping  longitudinal and cross-
sectional studies in our laboratory. Lipid measurements were carried out by Vascular Biochemistry, 
University of Glasgow a Centre for Disease Control (CDC) UK laboratory for the Lipid Standardisation 
Programme (cholesterol, triglyceride, HDL-C) and the CDC Reference Laboratory for cholesterol and 
HDL-C, thus lipid measurements are standardised over time. 
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